- Regencell Bioscience Holdings Ltd's RGC subsidiary in Hong Kong has entered into a joint venture agreement with Honor Epic Enterprises Limited to offer COVID-19 related treatments.
- The joint venture will cater to patients in ASEAN countries, India, Japan, Australia, and New Zealand. Regencell will own 60% of the JV with a customary drag-along option.
- The principal business of the JV shall be to trade, manufacture, market, and distribute Traditional Chinese Medicine (TCM) formulae products.
- TCM has so far treated 12 patients (suspected or confirmed COVID cases) after an average treatment period of 5 days, the Company said.
- Price Action: RGC stock is up 2.31% at $32.37 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsSmall CapMoversTrading IdeasGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
